Price List - Rhapsido - Atopy - NA.xlsx
XLSX spreadsheet 46 KB Posted
- Solicitation number
- HT9402-26-Q-9102
- Issued by
-
Defense Health Agency
About this file
This is a Price List Excel file for the Department of Defense (DoD) Pharmacy Uniform Formulary Blanket Purchase Agreement (BPA) and Additional Discount Program (ADP) for newly approved pharmaceutical drugs in the Atopy drug class. The document is for the February 2026 DoD Pharmacy and Therapeutics (P&T) Committee Meeting, with quotes due on December 9, 2025. The file contains pricing and formulary scenarios for 10 newly approved drugs, with potential placement in Uniform Formulary (UF), Non-Formulary (NF), Tier 2, or Tier 3 categories.
The document includes detailed pricing appendices for both Blanket Purchase Agreement and Additional Discount Program, with specific pricing and refund calculation methodologies. Key notes indicate that Prior Authorization (PA) may apply, and the P&T Committee can recommend preferential status, cost-sharing adjustments, or exclusion from the TRICARE pharmacy benefit program. The pricing calculations involve complex formulas using Non-Federal Average Manufacturer Price (non-FAMP), Federal Ceiling Price (FCP), Wholesale Acquisition Cost (WAC), and additional offered refund percentages. Manufacturers are instructed to submit fully executed signature pages with quote information.
View the file
Other files
| File | Type | Posted |
|---|---|---|
| Price List - Lynkuet - Gynecological Agents Misc- NA.xlsx | XLSX spreadsheet | |
| RFQ HT9402-26-Q-9102 NAD.pdf | ||
| Price List - Vyscoxa - Pain Agents - NSAID.xlsx | XLSX spreadsheet | |
| Price List - Palsonify - Endocrine Agents Misc - NA.xlsx | XLSX spreadsheet | |
| DoD Formulary Placement of FDA Newly Approved Drugs.pdf | ||
| Price List - Jascayd - Pulmonary-1- Idiopathic PF.xlsx | XLSX spreadsheet | |
| Price Appendix FAQ NAD.pdf | ||
| Price List - Tonmya - SMRs and Comb - TCA.xlsx | XLSX spreadsheet |
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
BPA
| UF BPA NDC Price List for the February 2026 DoD P&T Meeting | |||
| DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | February 4-5, 2026 |
| DOD Uniform Formulary Subclass: | N/A | Quotes due: | December 9, 2025 |
| Formulary Notes | |||
| Class Note(s): Prior Authorization (PA) may apply and allows for a step that includes any/all generic agents for all new and current users. Agents where no brand currently exists may be considered for tier designation. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program. |
Step Therapy Addendum: Agents with RFQ not submitted or selected may be designated non-step preferred (after-step).
Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.
The price per unit of measure for a given dosage form and strength (each, gram, mL, etc.) of the pharmaceutical agent will be the same for all available package sizes (e.g., 30s, 100s, 1000s) within a given dispensing venue.
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #1 | DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | February 4-5, 2026 | ||
| DOD Uniform Formulary Subclass: | N/A | Quotes due: | December 9, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 211ATNAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 211ATNAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #2 | DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | February 4-5, 2026 | ||
| DOD Uniform Formulary Subclass: | N/A | Quotes due: | December 9, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 211ATNAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 211ATNAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #3 | DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | February 4-5, 2026 | ||
| DOD Uniform Formulary Subclass: | N/A | Quotes due: | December 9, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 211ATNAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 211ATNAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #4 | DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | February 4-5, 2026 | ||
| DOD Uniform Formulary Subclass: | N/A | Quotes due: | December 9, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 211ATNAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 211ATNAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #5 | DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | February 4-5, 2026 | ||
| DOD Uniform Formulary Subclass: | N/A | Quotes due: | December 9, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 211ATNAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 211ATNAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #6 | DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | February 4-5, 2026 | ||
| DOD Uniform Formulary Subclass: | N/A | Quotes due: | December 9, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 211ATNAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 211ATNAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #7 | DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | February 4-5, 2026 | ||
| DOD Uniform Formulary Subclass: | N/A | Quotes due: | December 9, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 211ATNAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 211ATNAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #8 | DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | February 4-5, 2026 | ||
| DOD Uniform Formulary Subclass: | N/A | Quotes due: | December 9, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 211ATNAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 211ATNAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #9 | DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | February 4-5, 2026 | ||
| DOD Uniform Formulary Subclass: | N/A | Quotes due: | December 9, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 211ATNAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 211ATNAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #10 | DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | February 4-5, 2026 | ||
| DOD Uniform Formulary Subclass: | N/A | Quotes due: | December 9, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 211ATNAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 211ATNAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
ADP (non-FAMP Discount)
| UF ADP Appendix for the February 2026 DoD P&T Meeting | |||
| DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | February 4-5, 2026 |
| DOD Uniform Formulary Subclass: | N/A | Quotes due: | December 9, 2025 |
| Formulary Notes | |||
| Class Note(s): Prior Authorization (PA) may apply and allows for a step that includes any/all generic agents for all new and current users. Agents where no brand currently exists may be considered for tier designation. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program |
Step Therapy Addendum: Agents with RFQ not submitted or selected may be designated non-step preferred (after-step).
Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.
* Total Calculated Refund Per FCP is calculated as: ((non-FAMP-FCP)+(non-FAMP*Y%)) = Total Calculated Refund **Based on the most recent annual non-FAMP (reported to the Department of Veterans Affairs) from which the current annual Federal Ceiling Price (FCP) calculated ceiling is derived. The current annual FCP and the annual non-FAMP from which it is derived will be applicable to all prescriptions filled during a calendar year. The quoted additional refund percentage will remain static during the life of the agreement but the most recent annual non-FAMP, and thus the calculated refund, may change each calendar year.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | February 4-5, 2026 | |||
| DOD Uniform Formulary Subclass: | N/A | Quotes due: | December 9, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 211ATNAG1T21M | Tier 2 | 1 or more | |
| 211ATNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | February 4-5, 2026 | |||
| DOD Uniform Formulary Subclass: | N/A | Quotes due: | December 9, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 211ATNAG1T21M | Tier 2 | 1 or more | |
| 211ATNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | February 4-5, 2026 | |||
| DOD Uniform Formulary Subclass: | N/A | Quotes due: | December 9, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 211ATNAG1T21M | Tier 2 | 1 or more | |
| 211ATNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | February 4-5, 2026 | |||
| DOD Uniform Formulary Subclass: | N/A | Quotes due: | December 9, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 211ATNAG1T21M | Tier 2 | 1 or more | |
| 211ATNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #5 | DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | February 4-5, 2026 | |||
| DOD Uniform Formulary Subclass: | N/A | Quotes due: | December 9, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 211ATNAG1T21M | Tier 2 | 1 or more | |
| 211ATNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | February 4-5, 2026 | |||
| DOD Uniform Formulary Subclass: | N/A | Quotes due: | December 9, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 211ATNAG1T21M | Tier 2 | 1 or more | |
| 211ATNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | February 4-5, 2026 | |||
| DOD Uniform Formulary Subclass: | N/A | Quotes due: | December 9, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 211ATNAG1T21M | Tier 2 | 1 or more | |
| 211ATNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | February 4-5, 2026 | |||
| DOD Uniform Formulary Subclass: | N/A | Quotes due: | December 9, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 211ATNAG1T21M | Tier 2 | 1 or more | |
| 211ATNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | February 4-5, 2026 | |||
| DOD Uniform Formulary Subclass: | N/A | Quotes due: | December 9, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 211ATNAG1T21M | Tier 2 | 1 or more | |
| 211ATNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #10 | DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | February 4-5, 2026 | |||
| DOD Uniform Formulary Subclass: | N/A | Quotes due: | December 9, 2025 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 211ATNAG1T21M | Tier 2 | 1 or more | |
| 211ATNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
ADP (WAC Discount)
| UF ADP Appendix for the February 2026 DoD P&T Meeting | |||
| DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | February 4-5, 2026 |
| DOD Uniform Formulary Subclass: | N/A | Quotes due: | December 9, 2025 |
| Formulary Notes | |||
| Class Note(s): Prior Authorization (PA) may apply and allows for a step that includes any/all generic agents for all new and current users. Agents where no brand currently exists may be considered for tier designation. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program. |
Step Therapy Addendum: Agents with RFQ not submitted or selected may be designated non-step preferred (after-step).
Notes to Manufacturers: Do not forget to submit fully executed signature pages along with quote information.
The Wholesale Acquisition Cost (WAC) is obtained from First Databank via daily price updates; it is maintained at the dispensing unit level to five (5) decimal places. If the WAC changes during a calendar quarter, an average WAC will be calculated on a daily weighted basis (per unit only).
WAC is ONLY used for products that do not have a FCP, such as diabetic supplies (i.e., test strips), and can also be applied to covered drugs.
*The quoted WAC Discount percentage will remain static during the life of the agreement.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | February 4-5, 2026 | ||
| DOD Uniform Formulary Subclass: | N/A | Quotes due: | December 9, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 211ATNAG1T21M | Tier 2 | 1 or more | |
| 211ATNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | February 4-5, 2026 | ||
| DOD Uniform Formulary Subclass: | N/A | Quotes due: | December 9, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 211ATNAG1T21M | Tier 2 | 1 or more | |
| 211ATNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | February 4-5, 2026 | ||
| DOD Uniform Formulary Subclass: | N/A | Quotes due: | December 9, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 211ATNAG1T21M | Tier 2 | 1 or more | |
| 211ATNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | February 4-5, 2026 | ||
| DOD Uniform Formulary Subclass: | N/A | Quotes due: | December 9, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 211ATNAG1T21M | Tier 2 | 1 or more | |
| 211ATNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #5 | DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | February 4-5, 2026 | ||
| DOD Uniform Formulary Subclass: | N/A | Quotes due: | December 9, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 211ATNAG1T21M | Tier 2 | 1 or more | |
| 211ATNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | February 4-5, 2026 | ||
| DOD Uniform Formulary Subclass: | N/A | Quotes due: | December 9, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 211ATNAG1T21M | Tier 2 | 1 or more | |
| 211ATNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | February 4-5, 2026 | ||
| DOD Uniform Formulary Subclass: | N/A | Quotes due: | December 9, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 211ATNAG1T21M | Tier 2 | 1 or more | |
| 211ATNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | February 4-5, 2026 | ||
| DOD Uniform Formulary Subclass: | N/A | Quotes due: | December 9, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 211ATNAG1T21M | Tier 2 | 1 or more | |
| 211ATNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | February 4-5, 2026 | ||
| DOD Uniform Formulary Subclass: | N/A | Quotes due: | December 9, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 211ATNAG1T21M | Tier 2 | 1 or more | |
| 211ATNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #10 | DOD Uniform Formulary Class: | ATOPY | P&T Committee Meeting: | February 4-5, 2026 | ||
| DOD Uniform Formulary Subclass: | N/A | Quotes due: | December 9, 2025 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 211ATNAG1T21M | Tier 2 | 1 or more | |
| 211ATNAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
File details come from the government source that posted it. Updated .